Growth Outlook | Will Focus On Manufacturing Peptide APIs For Innovators: Neuland Labs | CNBC TV18
CNBC-TV18 · 23 Sept 2026 · 9 min
Management interview of Neuland Laboratories Ltd (NEULANDLAB), with 4 key numbers discussed.
- Saharsh Davuluri, CEO & MD, Neuland Laboratories Ltd
Neuland Labs has operationalized its brand-new peptide facility in Hyderabad, focusing on CDMO manufacturing for pharma innovators. The overall facility involves an investment of close to USD 30mn, with Module 1 accounting for around USD 20mn. Two clinical pipeline projects are expected to occupy most of Module 1's capacity. Management anticipates asset turns of around 1.5x to 2x for Module 1, slightly below the company's average of 2.5x. Expansion into Module 2 will be considered once Module 1 gets filled and reactor requirements become clearer.